Fast Facts
- FDA again delayed Savara’s Molbreevi decision, missing November 22 without setting a new deadline.
- The inhaled drug could become the first approved treatment for autoimmune pulmonary alveolar proteinosis.
- Stock fell 18% after announcement; analysts cite FDA capacity issues, not rejection.
- Phase 3 data and analyst confidence support approval; peak sales could exceed $500 million.
A rare-disease decision is delayed again
The FDA will miss its Nov. 22 decision date for Savara’s inhaled drug candidate, molgramostim, which may be marketed as Molbreevi. The agency has not provided a new date.
The decision was already delayed by three months in April. At that time, the FDA said Savara’s answers to its questions required a major amendment to the application. Savara said the earlier delay was not related to safety, effectiveness or manufacturing.
Promise for patients, uncertainty for investors
Molgramostim is being developed for autoimmune pulmonary alveolar proteinosis, or PAP, a rare lung disease that can cause serious complications, including lung scarring. If approved, it would be the first FDA-approved treatment for the condition.
In a 48-week trial, the drug improved a measure of lung function compared with a placebo at 24 weeks, meeting the study’s main goal. Still, a delayed decision leaves patients and investors waiting. Savara shares fell 18% at Friday’s market open.
More review time, but no new deadline
Analysts at Jefferies and Guggenheim said they remain confident in the drug’s prospects, pointing to the trial results and Savara’s work to address manufacturing questions. However, the FDA has not explained why it needs more time. The delay alone does not confirm approval—or rejection.
For people living with PAP, an approved inhaled treatment could offer a new option and improve daily life. Yet the next step is unclear. The FDA’s decision will determine whether the promising research becomes an available treatment.
Continue Your Tech Journey
Explore the future of technology with our detailed insights on Artificial Intelligence.
Stay inspired by the latest discoveries from NASA.
Sci-BioV1
